Where is Verrica Pharmaceuticals headquartered?

Verrica Pharmaceuticals is recorded with headquarters in West Chester, USA in NovaPharmaNews public regulatory and sponsor datasets.

Is Verrica Pharmaceuticals publicly traded?

Yes — Verrica Pharmaceuticals is listed as a public company with ticker VRCA on NYSE in SEC EDGAR-derived records.

What drugs are associated with Verrica Pharmaceuticals?

We link 1 drug profile(s) where Verrica Pharmaceuticals appears as originator or marketer in FDA or regional approval metadata.

What clinical trials is Verrica Pharmaceuticals sponsoring?

Verrica Pharmaceuticals is linked to 7 pipeline program(s) sourced from ClinicalTrials.gov and EU CTIS where sponsor names match.

What patents list Verrica Pharmaceuticals as applicant?

7 USPTO PatentsView record(s) name Verrica Pharmaceuticals or a normalized variant as applicant.

What pipeline phases does Verrica Pharmaceuticals have in our database?

Phase distribution from linked programs: phase 2: 4, phase 3: 3.

How many US-approved drugs are linked to Verrica Pharmaceuticals?

1 linked drug profile(s) include US approval status in openFDA-derived metadata.

Where does NovaPharmaNews source data on Verrica Pharmaceuticals?

Profiles combine SEC EDGAR (US issuers), FDA openFDA, EMA medicines data, ClinicalTrials.gov, EU CTIS, USPTO PatentsView, and regional PBS/PMDA/NMPA feeds. See /about/data-sources.

Is Verrica Pharmaceuticals data investment advice?

No. This profile is compiled from public regulatory records for professional reference only, not investment or medical advice.

Is Verrica Pharmaceuticals data investment advice?

No. This profile is compiled from public regulatory records for professional reference only, not investment or medical advice.

Verrica Pharmaceuticals Pharmaceuticals Company Profile

Name: Verrica Pharmaceuticals intelligence dataset
Creator: NovaPharmaNews
License: https://www.sec.gov/edgar.shtml

Company details

Status: Public
HQ: West Chester, USA
Founded: 2013
Employees: 80
Programs: 7
Drugs: 3
Patents: 7

Official website ↗ All projects Drug pipeline Patents News & analysis

Quick answer

Verrica Pharmaceuticals is a pharma organization headquartered in West Chester, USA. It trades on NYSE under ticker VRCA. Primary therapeutic focus areas include Molluscum Contagiosum, Common Warts (Verruca Vulgaris), Basal Cell Carcinoma, Condylomata Acuminata, Common Wart. NovaPharmaNews links 7 clinical program(s), 1 drug profile(s), and 7 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (4), phase 3 (3).

Company snapshot

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. We believe there’s a better way to safely and effectively bring relief to patients, deliver peace of mind to parents and caregivers, and advance accessible therapies to prescribers and payers. We are focused on changing the narrative around skin diseases and

1 approved product(s) across US/EU regulatory metadata.
7 active pipeline program(s) linked via ClinicalTrials.gov.
7 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Verrica Pharmaceuticals. Not investment advice.

Top assets

View drugs (3) View projects (7)

Lead pipeline drugs

adalimumab
approved
cantharidin
approved
solution
Marketed / approved
cantharidin Common Warts (Verruca Vulgaris)
Phase 3

Active clinical programs

Cantharidin Common Warts (Verruca Vulgaris)
Phase 3
VP-102 Common Warts
Phase 3
VP-102-101 Molluscum Contagiosum
Phase 3
Part 1: VP-315 3 Day Dosing/Week Basal Cell Carcinoma
Phase 2

Momentum

Proprietary activity score for Verrica Pharmaceuticals.

1 active signal

20 /100 +0 vs 30 days ago

Signal breakdown

Clinical trials 8 30d
Nova articles 0 30d
Patents filed 0 30d
FDA actions 0 30d
SEC filings 0 30d
Conference presentations 0 90d
Pipeline advances 0 30d

Competitor landscape

Therapeutic-area overlap peers from registry and pipeline signals.

Peer + 0 momentum

Aclaris Therapeutics

TA overlap score 26.6

Recent activity

Latest pipeline, patent, and corporate events for Verrica Pharmaceuticals.

Jun 8, 2026 Clinical update
VP-102-101 — Phase 3
Jun 8, 2026 Clinical update
VP-102 Cantharidin topical film forming solution — Phase 2
Jun 8, 2026 Clinical update
Part 1: VP-315 3 Day Dosing/Week — Phase 2
May 23, 2026 Clinical update
Cantharidin — Phase 3
May 23, 2026 Clinical update
VP-102 — Phase 3

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

What is Verrica Pharmaceuticals?

Verrica Pharmaceuticals is a pharma organization headquartered in West Chester, USA. It trades on NYSE under ticker VRCA. Primary therapeutic focus areas include Molluscum Contagiosum, Common Warts (Verruca Vulgaris), Basal Cell Carcinoma, Condylomata Acuminata, Common Wart. Nova
Is Verrica Pharmaceuticals publicly traded?

Yes. Verrica Pharmaceuticals is listed with ticker VRCA on NYSE per SEC EDGAR records linked on this profile.
What drugs does Verrica Pharmaceuticals develop or market?

We link 3 drug profile(s) where Verrica Pharmaceuticals is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/verrica-pharmaceuticals#company-drugs.
What are the latest developments for Verrica Pharmaceuticals?

In the last 12 months our linked public records show 7 trial program update(s) and 0 US patent grant(s) tied to this profile.
What therapeutic areas does Verrica Pharmaceuticals focus on?

Verrica Pharmaceuticals focuses on Molluscum Contagiosum, Common Warts (Verruca Vulgaris), Basal Cell Carcinoma based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others